Lindsey Shapiro, PhD,  science writer—

Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…

Nearly 18% of people with autoimmune hemolytic anemia (AIHA), of which cold agglutinin disease (CAD) is one type, were hospitalized due to an infection within six months of their first rituximab infusion, according to a French study. Patients particularly at risk for infection-related hospitalizations were those older than…

Managing the life-threatening consequences of a rare autoimmune condition called ANCA-associated vasculitis (AAV) can be particularly challenging when cold agglutinin disease (CAD) is also present, according to a recent case report. In this first documented case of AAV co-occurring with CAD, scientists described how the cold temperature of…

Long-term treatment with Enjaymo (sutimlimab) leads to sustained reductions in red blood cell destruction, anemia, and fatigue, as well as life quality improvements, in adults with cold agglutinin disease (CAD). That’s according to data from the extension portion (Part B) of the global Phase 3 CADENZA clinical…

Distinguishing between primary and secondary cold agglutinin disease (CAD), as well as understanding if cancer is the underlying cause of secondary CAD, is critical to ensure patients get the right treatment, according to a recent review study. Primary CAD — sometimes known simply as CAD — is not…

Nearly 20% of people with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), who required blood transfusions developed antibodies against proteins in donor blood that could compromise a transfusion’s safety or effectiveness, a study shows. These antibodies, called alloantibodies, were associated with a higher transfusion burden, lower…

Treatment with rituximab led to improvements in biomarkers of red blood cell destruction among people with cold agglutinin disease (CAD), but the  improvements often were short-lived and reversible, according to a real-world analysis in the U.S. The therapy, which often is used off-label for the rare autoimmune disease, also…

A free symposium on complement cascade-targeted treatment approaches for cold agglutinin disease (CAD) will be held live and virtually today ahead of the 2023 American Society of Hematology (ASH) meeting taking place in San Diego, California, Dec. 9-12. Announced in a tweet earlier this week, the session titled…

Among people with cold agglutinin disease (CAD), more than half were found to have a related autoimmune disorder called cryoglobulinemia, which affected symptom presentation but did not appear to affect survival. That’s according to a small study in which 59% of CAD patients tested positive for cryoglobulins, the…

Long-term treatment with Enjaymo (sutimlimab-jome) led to sustained improvements in life quality and reductions in fatigue for people with cold agglutinin disease (CAD), according to 2.5 years of data from the Phase 3 CARDINAL clinical trial. “[Enjaymo] provides sustained and durable treatment benefits in chronic CAD, including a…